Summarized by Masters of Longevity from Longevity Technology.
A development-focused piece describing a new cerebrospinal fluid assay intended to help clinicians and researchers tell atypical parkinsonian syndromes apart from Parkinson’s disease, highlighting the test’s purpose and clinical relevance.
Key Takeaways
- Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.
- Amprion has launched SAAmplify-αSYN Plus, a next-generation cerebrospinal fluid test designed to detect alpha-synuclein aggregates with an MSA-like amplification profile, and made it available on 15 September 2026.
